Research programme: prostanoid EP1 antagonists - GlaxoSmithKlineAlternative Names: GW 848687X
Latest Information Update: 18 Apr 2011
At a glance
- Originator GlaxoSmithKline
- Mechanism of Action Prostaglandin-E EP1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammatory pain
Most Recent Events
- 20 Oct 2006 Preclinical trials in Inflammatory pain in England (unspecified route)